8,560 Gilead Sciences, Inc. $GILD Shares Sold by Kelleher Financial Advisors

Kelleher Financial Advisors reduced its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 49.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 8,654 shares of the biopharmaceutical company’s stock after selling 8,560 shares during the quarter. Kelleher Financial Advisors’ holdings in Gilead Sciences were worth $1,290,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. BlackRock Inc. bought a new position in Gilead Sciences in the 2nd quarter valued at $15,393,785,000. State Street Corp raised its stake in shares of Gilead Sciences by 2.3% during the 2nd quarter. State Street Corp now owns 61,216,552 shares of the biopharmaceutical company’s stock worth $7,734,099,000 after purchasing an additional 1,357,967 shares during the period. Amundi raised its stake in shares of Gilead Sciences by 10.7% during the 1st quarter. Amundi now owns 10,539,111 shares of the biopharmaceutical company’s stock worth $1,468,836,000 after purchasing an additional 1,018,976 shares during the period. Legal & General Group Plc purchased a new position in shares of Gilead Sciences in the 2nd quarter worth about $1,316,606,000. Finally, Deutsche Bank AG purchased a new position in shares of Gilead Sciences in the 2nd quarter worth about $918,387,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on GILD. Jefferies Financial Group set a $196.00 price target on shares of Gilead Sciences in a research report on Wednesday. Royal Bank Of Canada boosted their target price on shares of Gilead Sciences from $126.00 to $131.00 and gave the company a “sector perform” rating in a research note on Friday, October 30th. UBS Group increased their target price on shares of Gilead Sciences from $175.00 to $195.00 and gave the company a “buy” rating in a research report on Friday, October 30th. Citigroup raised their price target on shares of Gilead Sciences from $165.00 to $188.00 and gave the stock a “buy” rating in a research note on Friday, October 30th. Finally, Zacks Research cut shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 29th. Twenty-three analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $170.15.

Insider Activity at Gilead Sciences

In related news, Director Anthony Welters sold 18,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $148.62, for a total value of $2,675,160.00. Following the completion of the transaction, the director directly owned 12,894 shares of the company’s stock, valued at approximately $1,916,306.28. This trade represents a 58.26% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $156.22, for a total transaction of $468,660.00. Following the completion of the transaction, the insider owned 113,684 shares of the company’s stock, valued at $17,759,714.48. This represents a 2.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 126,881 shares of company stock worth $19,252,455 in the last ninety days. Insiders own 0.30% of the company’s stock.

Gilead Sciences Stock Up 4.2%

GILD stock opened at $174.48 on Thursday. The stock has a fifty day moving average of $152.29 and a 200-day moving average of $140.52. Gilead Sciences, Inc. has a fifty-two week low of $116.88 and a fifty-two week high of $175.65. The company has a market capitalization of $216.41 billion, a price-to-earnings ratio of -55.22 and a beta of 0.35. The company has a debt-to-equity ratio of 1.84, a quick ratio of 0.95 and a current ratio of 1.38.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.19 by $0.36. The business had revenue of $8.30 billion for the quarter, compared to analysts’ expectations of $7.81 billion. Gilead Sciences had a negative return on equity of 1.85% and a negative net margin of 12.47%. The firm’s quarterly revenue was up 6.8% compared to the same quarter last year. During the same period in the previous year, the business posted $2.47 EPS. As a group, equities research analysts predict that Gilead Sciences, Inc. will post -1.07 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be given a $0.82 dividend. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $3.28 annualized dividend and a dividend yield of 1.9%. Gilead Sciences’s payout ratio is -103.80%.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: DZ Bank raised its price target on Gilead to $191 from $167, signaling increased confidence in the stock’s prospects. DZ Bank Adjusts Price Target on Gilead Sciences to $191 From $167
• Positive Sentiment: Gilead and its Kite subsidiary plan 23 presentations, including seven oral presentations, at the December ASH meeting. The breadth of planned data across the pipeline and portfolio may draw investor attention to potential growth drivers. Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026
• Positive Sentiment: BioNTech and Gilead are advancing a global Phase 3 trial combining BioNTech’s pumitamig with Gilead’s cancer drug Trodelvy (sacituzumab govitecan) for metastatic triple-negative breast cancer. The collaboration expands the potential reach of Gilead’s oncology portfolio, though trial results remain to come. BioNTech Enters First Global Phase 3 Trial for New Breast Cancer Combo
• Neutral Sentiment: Gilead’s GS-1206 cancer study continues to advance, but investors are still waiting for early efficacy signals; the update did not provide results that establish the drug’s potential. Gilead’s GS-1206 Cancer Trial Advances as Investors Watch for Early Signals
• Negative Sentiment: Put-option purchases were unusually elevated, which may reflect increased hedging or bearish positioning, though options activity alone does not confirm a negative outlook.
• Negative Sentiment: CEO Daniel O’Day disclosed recent stock sales under a pre-arranged Rule 10b5-1 plan. The planned nature of the sales may limit their significance, but insider selling can still weigh on sentiment.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.